“All people with diabetes in Georgia, particularly children, are fully supplied with insulin from French company Sanofi Aventis,” Health Minister Mikheil Sarjveladze stated at a briefing, emphasising that no supply disruption exists or will occur.

However, Danish company Novo Nordisk, which produces a second popular insulin type, has breached its contract signed on April 14. The company supplied far less medication than planned, and with delays, failing to fulfil its obligations despite promises.

“Regrettably, the company is flagrantly violating its obligations. We communicated with senior leadership, and I personally met them in October. They promised delivery by early November, yet the obligation remains unfulfilled,” the Minister stated.

He noted that, considering parents’ preference for Novo Nordisk’s product, authorities are trying to avoid strict decisions, acting solely in patients’ interests.

“Our priority is protecting our population. We need partners who put Georgian patients first. Every doctor is prepared to manage medication substitution if necessary. Parents are clearly informed that access to Sanofi medication faces no risk,” Mr Sarjveladze emphasised.

The Minister dismissed claims of insulin shortages as “deliberate spread of lies,” stating: “Not a single child has been left without insulin. Even the risk of this is excluded.”